News

Filter

Current filters:

OnglyzaPharmaceutical

1 to 9 of 19 results

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

FDA to review heart failure risk with AstraZeneca diabetes drug

FDA to review heart failure risk with AstraZeneca diabetes drug

12-02-2014

The US Food and Drug Administration has requested clinical trial data from Anglo-Swedish drug major AstraZeneca,…

AstraZenecaDiabetesKombiglyzeNorth AmericaOnglyzaPharmaceuticalRegulationResearchUSA

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

19-12-2013

Confirming recent runors, Anglo-Swedish drug major AstraZeneca revealed this morning that it will acquire…

AstraZenecaBristol-Myers SquibbDiabetesExenatide InjectionMergers & AcquisitionsOnglyzaPharmaceutical

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

05-12-2013

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

AstraZenecaBristol-Myers SquibbDiabetesEuropeOnglyzaPharmaceuticalPricingRegulation

Bristol-Myers Squibb releases strong third quarter results

Bristol-Myers Squibb releases strong third quarter results

23-10-2013

Bristol-Myers Squibb has announced strong third quarter results with sales up 9% to $4.1 billion.

BaracludeBristol-Myers SquibbFinancialNorth AmericaOnglyzaOrenciaPharmaceuticalSprycelYervoy

New hypoglycemia and pancreatitis sub-analyses from the Onglyza SAVOR study released at EASD

New hypoglycemia and pancreatitis sub-analyses from the Onglyza SAVOR study released at EASD

27-09-2013

Bristol-Myers Squibb and partner AstraZeneca have announced additional results from the SAVOR cardiovascular…

AstraZenecaBristol-Myers SquibbDiabetesOnglyzaPharmaceuticalResearch

Onglyza meets primary safety endpoint in SAVOR CV outcomes trial

02-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today…

AstraZenecaBristol-Myers SquibbCardio-vascularDermatologicalsOnglyzaPharmaceuticalResearch

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

1 to 9 of 19 results

Back to top